Fulvestrant for the treatment of endometrial cancer

References

• Ferlay J, Soerjomataram II, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86.
   PubMed Web of Science ®Google Scholar
• Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005;366:491–505.
   PubMed Web of Science ®Google Scholar
• Battista MJ, Steiner E, Rieks N, et al. Nationwide analysis on surgical staging procedures and systemic treatment for patients with endometrial cancer in Germany. Int J Gynecol Cancer. 2013;23:105–112.
   PubMed Web of Science ®Google Scholar
• Fleisch MC, Pantke P, Beckmann MW, et al. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers. J Surg Oncol. 2007;95:476–484.
   PubMed Web of Science ®Google Scholar
• Westin SN, Rallapalli V, Fellman B, et al. Overall survival after pelvic exenteration for gynecologic malignancy. Gynecol Oncol. 2014;134:546–551.
   PubMed Web of Science ®Google Scholar
• Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control. 2009;16:38–45.
   PubMed Web of Science ®Google Scholar
• Creutzberg CL, Van Putten WL, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol. 2003;89:201–209.
   PubMed Web of Science ®Google Scholar
• Sommeijer DW, Sjoquist KM, Friedlander M. Hormonal treatment in recurrent and metastatic gynaecological cancers: a review of the current literature. Curr Oncol Rep. 2013;15:541–548.
   PubMed Web of Science ®Google Scholar
• Bradford LS, Rauh-Hain JA, Schorge J, et al. Advances in the management of recurrent endometrial cancer. Am J Clin Oncol. 2015;38:206–212.
   PubMed Web of Science ®Google Scholar
• Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer. 2007;17:964–978.
   PubMed Web of Science ®Google Scholar
• Battista M, Stickeler E, Schmidt M. Prädiktive Faktoren in der metastasierten Situation. Gynakologe. 2015;48:885–890. doi:10.1007/s00129-015-3803-z.
   Google Scholar
• Battista MJ, Schmidt M, Rieks N, et al. Adjuvant treatment decisions for patients with endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009, and 2006. J Cancer Res Clin Oncol. 2015;141:555–562.
   PubMed Web of Science ®Google Scholar
• Nagao S, Nishio S, Michimae H, et al. Applicability of the concept of “platinum sensitivity” to recurrent endometrial cancer: the SGSG-012/GOTIC-004/Intergroup study. Gynecol Oncol. 2013;131:567–573.
   PubMed Web of Science ®Google Scholar
• Battista MJ, Schmidt M, Eichbaum M, et al. Management of recurrent or metastatic endometrial cancer in Germany: results of the nationwide AGO pattern of care studies from the years 2013, 2009 and 2006. Arch Gynecol Obstet. 2015;292:1355–1360.
   PubMed Web of Science ®Google Scholar
• Thigpen BJT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose - response study by the Gynecologic O ncology Group. J Clin Oncol. 1999;17:1736–1744.
   PubMed Web of Science ®Google Scholar
• Lentz SS, Brady MF, Major FJ, et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 1996;14:357–361.
   PubMed Web of Science ®Google Scholar
• Thigpen T, Blessing J, Disaia P, et al. Oral medroxyprogesterone acetate in advanced or recurrent endometrial carcinoma: results of therapy and correlation with estrogen and progesterone receptor levels. The Gynecologic Oncology Group experience. In: Baulier E, Iacobelli S, McGuire WW, editors. Endocrinology and malignancy. 1986. p. 446–454.
   Google Scholar
• Rendina G, Donadio C, Fabri M, et al. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obs Gynecol Reprod Bio. 1984;17:285–291.
   PubMed Web of Science ®Google Scholar
• Thigpen BT, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol. 2001;19:364–367.
   PubMed Web of Science ®Google Scholar
• Pandya KJ, Yeap BY, Weiner LM, et al. Megestrol and tamoxifen in patients with advanced endometrial cancer: an Eastern Cooperative Oncology Group Study (E4882). Am J Clin Oncol. 2001;24:43–46.
   PubMed Web of Science ®Google Scholar
• Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma : a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:10–14.
   PubMed Web of Science ®Google Scholar
• Whitney C, Brunetto VL, Zaino RJ, et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:4–9.
   PubMed Web of Science ®Google Scholar
• Covens A, Thomas G, Shaw P, et al. A phase II study of leuprolide in advanced/recurrent endometrial cancer. Gynecol Oncol. 1997;64:126–129.
   PubMed Web of Science ®Google Scholar
• Lhomme C, Vennin P, Callet N, et al. A multicenter phase II study with triptorelin (sustained-release lhrh agonist) in advanced or recurrent endometrial carcinoma: a French Anticancer Federation study. Gynecol Oncol. 1999;75:187–193.
   PubMed Web of Science ®Google Scholar
• Asbury RF, Brunetto VL, Lee RB, et al. Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol. 2002;25:557–560.
   PubMed Web of Science ®Google Scholar
• Rose PG, Brunetto VL, VanLe L, et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2000;78:212–216.
   PubMed Web of Science ®Google Scholar
• Ma B, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers–a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer. 2004;14:650–658.
   PubMed Web of Science ®Google Scholar
• Tsoref D, Welch S, Lau S, et al. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecol Oncol. 2014;135:184–189.
   PubMed Web of Science ®Google Scholar
• Colombo N, McMeekin DS, Schwartz PE, et al. Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial. Br J Cancer. 2013;108:1021–1026.
   PubMed Web of Science ®Google Scholar
• Oza A, Pignata S, Poveda A, et al. Randomized phase II trial of ridaforolimus in advanced endometrial carcinoma. J Clin Oncol. 2015;33:3576–3582.
   PubMed Web of Science ®Google Scholar
• Fleming GF, Filiaci VL, Marzullo B, et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2014;132:585–592.
   PubMed Web of Science ®Google Scholar
• Oza AM, Elit L, Tsao M-S, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29:3278–3285.
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Favier L, Weber B, et al. Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer. 2013;108:1771–1777.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116:5415–5419.
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Jiang Y, Yates MS, et al. Phase II study of everolimus and letrozole in patients with recurrent endometrial carcinoma. J Clin Oncol. 2015;33:930–936.
   PubMed Web of Science ®Google Scholar
• Quinn M, Campbell J. Tamoxifen therapy in advanced/recurrent endometrial carcinoma. Gynecol Oncol. 1989;32:1–3.
   PubMed Web of Science ®Google Scholar
• Hald I, Salimtschik H, Mouridsen H. Tamoxifen treatment of advanced endometrial carcinoma. A phase II study. Eur J Gynaecol Oncol. 1983;4:83–87.
   PubMedGoogle Scholar
• Slavik M, Petty W, Blessing JA, et al. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep. 1984;68:809–811.
   PubMedGoogle Scholar
• Kline R, Freedman R, Jones L, et al. Treatment of recurrent or metastatic poorly differentiated adenocarcinoma of the endometrium with tamoxifen and medroxyprogesterone acetate. Cancer Treat Rep. 1987;71:327–328.
   PubMedGoogle Scholar
• Covens AL, Filiaci V, Gersell D, et al. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;120:185–188.
   PubMed Web of Science ®Google Scholar
• Emons G, Günthert A, Thiel FC, et al. Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynäkologische Onkologie. Gynecol Oncol. 2013;129:495–499.
   PubMed Web of Science ®Google Scholar
• Humber CE, Tierney JF, Symonds RP, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol. 2007;18:409–420.
   PubMed Web of Science ®Google Scholar
• Ball HG, Blessing JA, Lentz SS, et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium : a gynecologic oncology group study 1. Gynecol Oncol. 1996;281:278–281.
   Web of Science ®Google Scholar
• Hirai Y, Hasumi K, Onose R, et al. Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese multicenter study group. Gynecol Oncol. 2004;94:471–476.
   PubMed Web of Science ®Google Scholar
• Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a gynecologic oncology group Study. J Clin Oncol. 2004;22:2159–2166.
   PubMed Web of Science ®Google Scholar
• Miller D, Filiaci V, Fleming G, et al. Late-breaking abstract 1: randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A gynecologic oncology group study. Gynecol Oncol. 2012;125:771.
   Web of Science ®Google Scholar
• Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: A gynecologic oncology group study. J Clin Oncol. 2011;29:2259–2265.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Sill MW, Lankes HA, et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2012;127:538–543.
   PubMed Web of Science ®Google Scholar
• Moore KN, Sill M, Tenney ME, et al. A phase II trial of trebaninib (AMG 386), a selective angiopoietin 1/2 neuralizing peptibody in patients with persistent/recurrent carcinoma of the endometrium: A Gynecologic Oncology Group study. Poster. Gynecol Oncol. 2015;137:24.
   Google Scholar
• Lincoln S, Blessing JA, Lee RB, et al. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol. 2003;88:277–281.
   PubMed Web of Science ®Google Scholar
• Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential a potent specific pure antiestrogen with clinical potential. Am Assoc Cancer Res. 1991;51:3867–3873.
   Google Scholar
• Frasor J, Stossi F, Danes JM, et al. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 2004;64:1522–1533.
   PubMed Web of Science ®Google Scholar
• Howell A, Osborne C, Morris C, et al. ICI 182,780 (Faslodex): development of a novel, “pure” antiestrogen. Cancer. 2000;89:817–825.
   PubMed Web of Science ®Google Scholar
• Wijayaratne AL, Nagel SC, Paige LA, et al. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology. 1999;140:5828–5840.
   PubMed Web of Science ®Google Scholar
• Dauvois S, Danielian PS, White R, et al. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci. 1992;89:4037–4041.
   PubMed Web of Science ®Google Scholar
• Fawell SE, White R, Hoare S, et al. Inhibition of estrogen receptor-DNA binding by the “pure” antiestrogen ICI 164,384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci. 1990;87:6883–6887.
   PubMed Web of Science ®Google Scholar
• Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 1993;106(Pt 4):1377–1388.
   PubMed Web of Science ®Google Scholar
• Suga S, Kato K, Ohgami T, et al. An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecol Oncol. 2007;105:341–350.
   PubMed Web of Science ®Google Scholar
• Regan RMO, Cisneros A, England GM, et al. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J Natl Cancer Inst. 1998;90:1552–1558.
   PubMedGoogle Scholar
• Thomas EJ, Walton PL, Thomas NM, et al. The effects of ICI 182,780, a pure anti-oestrogen, on the hypothalamic-pituitary-gonadal axis and on endometrial proliferation in pre-menopausal women. Hum Reprod. 1994;9:1991–1996.
   PubMed Web of Science ®Google Scholar
• Addo S, Yates RA, Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br J Cancer. 2002;87:1354–1359.
   PubMed Web of Science ®Google Scholar
• Krell J, Januszewski A, Yan K, et al. Role of fulvestrant in the management of postmenopausal breast cancer. Expert Rev Anticancer Ther. 2011;11:1641–1652.
   PubMed Web of Science ®Google Scholar
• Robertson JF, Erikstein B, Osborne K, et al. Pharmacokinetic profile of intramuscular fulvestrant in advanced breast cancer. Clin Pharmocokinet. 2004;43:529–538.
   Google Scholar
• Howell A, De Friend DJ, Robertson JF, et al. Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancer. Br J Cancer. 1996;74:300–308.
   PubMed Web of Science ®Google Scholar
• Howell A, De Friend D, Robertson RW, et al. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 1995;375:29–30.
   Web of Science ®Google Scholar
• Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008;26:1664–1670.
   PubMed Web of Science ®Google Scholar
• Robertson JFR, Llombart-Cussac A, Rolski J, et al. FIRST Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27:4530–4535.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28:4594–4600.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. JNCI J Natl Cancer Inst. 2014;106:djt337–djt337.
   Web of Science ®Google Scholar
• Emons G, Bock N, Hellriegel M. Endokrine therapie des endometriumkarzinoms. Gynakologe. 2012;45:613–617.
   Google Scholar
• Lux MP, Wenkel EM, Beckmann K, et al. Fulvestrant: a further treatment option for patients with metastatic uterine cancer? Onkologie. 2006;29:577–580.
   PubMedGoogle Scholar
• Hoffman MA, Khan A. Durable response of metastatic endometrial carcinoma to treatment with fulvestrant (Faslodex) after prior progestin and anastrozole therapy. Gynecol Oncol. 2006;100:439–441.
   PubMed Web of Science ®Google Scholar
• Howell A, Robertson J, Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20:3396–3403.
   PubMed Web of Science ®Google Scholar